Drugs Made In America Acquisition II Corp. (DMII)
NASDAQ: DMII · Real-Time Price · USD
10.02
-0.01 (-0.10%)
Dec 5, 2025, 4:00 PM EST - Market closed
Company Description
Drugs Made In America Acquisition II Corp. does not have significant operations.
It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.
The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Drugs Made In America Acquisition II Corp.
| Country | United States |
| Founded | 2024 |
| IPO Date | Sep 25, 2025 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Lynn Stockwell |
Contact Details
Address: 1 East Broward Boulevard, Suite 700 Fort Lauderdale, Florida 33301 United States | |
| Phone | 954 870 3099 |
Stock Details
| Ticker Symbol | DMII |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0002040475 |
| ISIN Number | KYG2851K1040 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Lynn Stockwell | Chief Executive Officer and Executive Chair of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2025 | 10-Q | Quarterly Report |
| Nov 18, 2025 | 8-K | Current Report |
| Nov 17, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Oct 2, 2025 | 8-K | Current Report |
| Oct 2, 2025 | SCHEDULE 13D | Filing |
| Sep 29, 2025 | 8-K | Current Report |
| Sep 25, 2025 | 424B4 | Prospectus |
| Sep 24, 2025 | EFFECT | Notice of Effectiveness |
| Sep 24, 2025 | CERT | Certification by an exchange approving securities for listing |
| Sep 24, 2025 | 8-A12B | Registration of securities |